A phase 2, open‐label study of single dose dupilumab in children aged 6 months to < 6 years with severe uncontrolled atopic dermatitis: Pharmacokinetics, safety and efficacy
Journal of the European Academy of Dermatology and Venereology | Sep 11, 2020